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Abstract
Introduction: Preclinical testing in animal models is a critical component of the drug
discovery and development process. While hundreds of interventions have demon-
strated preclinical efficacy for ameliorating cognitive impairments in animal models,
none have confirmed efficacy in Alzheimer’s disease (AD) clinical trials. Critically this
lack of translation to the clinic points in part to issues with the animal models, the pre-
clinical assays used, and lack of scientific rigor and reproducibility during execution. In
an effort to improve this translation, the Preclinical Testing Core (PTC) of the Model
Organism Development and Evaluation for Late-onset AD (MODEL-AD) consortium
has established a rigorous screening strategy with go/no-go decision points that per-
mits unbiased assessments of therapeutic agents.
Methods:An initial screen evaluates drug stability, formulation, and pharmacokinetics
(PK) to confirm appreciable brain exposure in the disease model at the pathologically
relevant ages, followed by pharmacodynamics (PD) and predictive PK/PDmodeling to
inform the dose regimen for long-term studies. The secondary screen evaluates tar-
get engagement and disease modifying activity using non-invasive positron emission
tomography/magnetic resonance imaging (PET/MRI). Provided the compound meets
its “go” criteria for these endpoints, evaluation for efficacy on behavioral endpoints are
conducted.
Results: Validation of this pipeline using tool compounds revealed the importance of
critical quality control (QC) steps that researchers need to be aware of when execut-
ing preclinical studies. These include confirmation of the active pharmaceutical ingre-
dient and at the precise concentration expected; and an experimental design that is
well powered and in line with the Animal Research Reporting of In vivo Experiments
(ARRIVE) guidelines.
Discussion: Taken together our experience executing a rigorous screening strategy
with QC checkpoints provides insight to the challenges of conducting translational
studies in animal models. The PTC pipeline is a National Institute on Aging (NIA)-
supported resource accessible to the research community for investigators to
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nominate compounds for testing (https://stopadportal.synapse.org/), and these
resources will ultimately enable better translational studies to be conducted.
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1 INTRODUCTION
Throughout the last several decades there have been considerable
efforts to develop disease-ameliorating treatments which stop, pre-
vent, or delay Alzheimer’s disease (AD).1,2 Unfortunately, while hun-
dreds of interventions froma range of drug classes have shownpreclin-
ical efficacy in ameliorating cognitive impairment and disease burden
in animal models, none to date have proven efficacious for improving
cognition in human clinical trials.2-4
Preclinical testing in animal models is a critical component of the
drugdiscovery anddevelopment process, to predict both a compound’s
efficacy and safety profile in the clinic. Historically, preclinical screen-
ing of test compounds for ADhave used behavioral endpoints in rodent
models as the primary screen.4 A review of the literature and the
Alzheimer’s disease preclinical efficacy database AlzPED (see https:
//alzped.nia.nih.gov), provides insight into these preclinical behavioral
studies which have often been misinterpreted, including ignoring con-
founds of hyperactivity and visual impairments on cognitive behav-
iors in aging animals, alongwith failure to determine pharmacokinetics
(PK) in the model system.5 These experiments have frequently failed
to transparently report critical details of the experimental design,
including rigor in methods for blinding, randomization, counterbalanc-
ing, inclusion of appropriate controls, and statistically powered sam-
ple size selection, which are fundamental aspects of Animal Research
Reporting of In vivo Experiments (ARRIVE) guidelines.5-8 Further, test-
ing has often been conducted in young animals, and often limited to
only one sex. Moreover, preclinical AD studies have rarely usedmolec-
ular biomarkers, or other clinically translational endpoints as PD read-
outs (ie, positron emission tomography/magnetic resonance imaging
[PET/MRI]).While there is value in functional, symptom-modifying out-
come measures, these should be considered once biomarker changes
have been shown to result in a dose-, or concentration-, dependent
manner consistent with target engagement in the tissue of interest.
Indeed,while themouse remains an important animalmodel system for
evaluating potential therapeutic efficacy for AD, it is imperative that
researchers promote responsible use of these models for preclinical
drug testing.
In an effort to improve preclinical to clinical translation, the Preclin-
ical Testing Core (PTC) of the Model Organism Development for Late
Onset Alzheimer’s Disease (MODEL-AD) consortium is responsive to
the 2012 and 2015 National Institute on Aging (NIA) AD Research
Summit recommendations on increasing the predictive power of pre-
clinical testing in animal models.8,9 This includes establishment of rig-
orous and standardized protocols, which implement best practices for
preclinical screening of therapeutic compounds, and importantly prior-
itizes PK and pharmacodynamics (PD) measures over cognitive mea-
sures as the primary screen in mouse models.8,9 Critically, all raw and
analyzed data, including negative and positive findings, are reported to
the public data repository (https://adknowledgeportal.synapse.org/).
2 METHODS
The PTC has established a rigorous screening strategy with a pri-
ori go/no-go decision points that allow unbiased assessments of
potential therapeutic agents and critical quality control (QC) check-
points as part of best practices (Figure 1). As part of establish-
ing this screening strategy, to optimize protocols and validate the
pipeline, the PTC evaluated a well-characterized clinical tool com-
pound, the beta-secretase one inhibitor MK-8931 (verubecestat). In
line with the PTC’s precision medicine approach, the mechanism of
action of verubecestat was matched to a well-characterized model
system with a relevant AD biomarker (eg, robust amyloid deposition)
that enabled in vivo target engagement; 5XFAD mice (B6.Cg-Tg [APP-
SwFlLon,PSEN1*M146L*L286V]6799Vas/Mmjax; JAX#34848). Prior
to initiating long term chronic dosing studies, qualification and
confirmation of the active pharmaceutical ingredient (API) by liq-
uid chromatography-mass spectrometry (LC/MS/MS) was performed,
along with drug formulation and stability assessments. Once con-
firmed, PK studies were conducted in 5XFAD mice (n = 3–4 per
sex/dose) at pathophysiological relevant ages (eg, 6 months) to con-
firm brain exposure. Predictive PK/PD modeling was conducted to
inform the study design, including optimal dosing regimens (ie, dose,
route, frequency) for long-term PD studies. After the primary screen,
non-invasive PET/MRI were conducted to evaluate target engagement
after chronic treatment (n = 10-15 per sex/dose). For the present
studies, the clinical radio-tracer 18F-AV45 PET was used to evaluate
alterations of amyloid as the PD endpoint. Mice were injected with
5 to 7MBq of 18F-AV45 via tail vein, allowed 30 minutes uptake in
their home cages, and then scanned for 15 minutes on IndyPET3. Cor-
rected images (ie, decay, scatter, dead-time, etc) were reconstructed
via filtered back-projection, registered to the Paxinos-Franklin atlas,
27 brain regions extracted, and standardized uptake value ratio (SUVR;
ie, relative to cerebellum) values computed. Provided the compound
meets its criteria for these endpoints, evaluation of behavioral end-
points are conducted. All experiments are conducted in line with
the ARRIVE guidelines and carried out in line with the National
Institutes of Health (NIH) guide for the care and use of laboratory
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animals (NIH Publications No. 8023, revised 1978).7 All detailedmeth-
ods and data including animal husbandry and breeding conditions as
well as assay standard operating procedures (SOPs) are available via
https://adknowledgeportal.synapse.org andwww.model-ad.org.9
3 RESULTS
The LC/MS/MS assay was developed in the Clinical Pharmacology
Analytical Core using verubecestat triflouroacetate purchased from
Selleck Chemicals (Cat #S8173; standard). Figure 2(A-D) shows the
resulting LC/MS/MS chromatograms of the verubecestat standard
(2A) and corresponding internal standard MK-2206 (2B), and the
custom batch API (2C) and corresponding MK-2206 (2D). Analysis of
the custombulk synthesis batch of verubecestat from the same vendor
was not detectable using this assay. To evaluate this discrepancy,
the method was transferred to a liquid chromatography/ultraviolet
(LC/UV) system (λ = 280 nm). Injecting both the standard and the
custom batch revealed that the standard eluted at 8.953 minutes
(2E) while the custom batch API eluted at 9.666 minutes (2F). Fur-
ther analyses concluded that the custom batch API did not contain
verubecestat. The vendor subsequently replaced the custom batch
API, which was confirmed as verubecestat. Acute oral administration
to 6months aged 5XFADmice for PK analysis revealed a short half-life
for verubecestat (ie, T1/2= 2.7 hours), which would require multiple
daily administrations via oral dosing over a 3-month period tomaintain
targeted exposure levels in the brain. To avoid significant stress and
attrition related to daily oral gavage, the API was sent to a commercial
vendor and milled into chow. Two batches of pellets underwent QC
prior to dosing, which revealed erroneous mislabeling by the vendor.
After correcting these anomalies, inter- and intra-pellet analyses
were conducted to confirm drug concentration in pelleted chow.
Inter-pellet analysis revealed an average 54 ± 17% and 59 ± 16% of
expected drug concentrations, in batch 1 and batch 2, respectively.
Intra-pellet analysis revealed unequal distribution with coefficient
of variation ranging from 8% to 36%. These data coupled with the
pilot PK data provided additional information for PK/PD modeling
to better calculate the range of drug concentrations required to be
formulated into chow to achieve adequate exposure levels in the brain.
The designated dose levels of 60, 100, and 600 parts per million were
therefore formulated to achieve estimated daily dosages of 10, 30, and
100 mg/kg/day, fed ad libitum in chow, and were in line with our PK
data and published EC50 for verubecestat.
10 Subsequently, analysis of
chronic verubecestat exposure on amyloid levels resulted in expected
dose dependent reductions in amyloid in both sexes as measured by
18F-AV45 PET SUVR, in line with clinical findings.10
4 DISCUSSION
Like most preclinical efficacy studies for AD, our pipeline includes
chronic dosing of test compound in aged mice. However, we also
include several crucial steps prior to the chronic dosing, namely: (1)
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using traditional (eg, PubMed) and new sources (eg,
AlzPED), as well as face to face discussions with scien-
tists on approaches to preclinical testing in animal mod-
els. It was clear that a majority of studies have not been
executed with the level of rigor used in clinical trials,
including gaps in methods for blinding, a priori inclu-
sion and exclusion criteria, predetermined sample sizes,
randomization, and data quality control measures. Fur-
ther, testing is often conducted opportunistically in the
animal model most readily available to the laboratory,
rather thanmatching themechanismof action to themost
appropriate model for in vivo target engagement and rel-
evant biomarkers.
2. Interpretation: Our findings highlight a need for
improved methodologies and resources for the research
community.
3. Future directions:We propose a framework for improved
rigor in preclinical testing that will ultimately enable bet-
ter translation from animal models to clinical studies.
QC and stability testing of the API; and (2) initial PK and PD modeling
to inform the dose regimen. These initial data confirm that the API is
the intended compound, and that the dose regimen selected achieves
the expected concentrations in the target tissue. Failure of either sce-
nario could result in false negative results, and months of wasted time,
efforts, resources, and precious animals. In the present studies, the
initial QC steps allowed us to correct issues with drug formulations
prior to advancing with the chronic study, whichwould have ultimately
resulted in unexplained failure. Moreover, QC of the drug concentra-
tion in the intended formulation, including in food, are critical aspects
for success. Ideally in vivo PK should be determined prior to initiat-
ing long term studies to understand the kinetic properties and drug
uptake at the active site. FormostAD therapies, thiswill include under-
standing of blood-brain barrier permeability and tissue exposure. At a
minimum, the API should be assessed in plasma and brain as part of
the terminal procedures to confirm target exposure. Importantly, these
aforementioned fail-safes permitted advancement of this study, and
resulted in the expected dose-dependent reduction in beta amyloid as
measured by 18F-AV45 PET SUVR.
5 CONCLUSIONS
Evaluation of potential therapeutic efficacy of test compounds in
animal models is not trivial. Emphasis on QC steps is an essential part
of rigor in experimental design, and unfamiliarity of these steps is an
unfortunate common point of failure. Our collective prior experience
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F IGURE 1 TheModel OrganismDevelopment for Late Onset Alzheimer’s Disease (MODEL-AD) Preclinical Testing Core (PTC) Drug
Screening pipeline. The PTC strategy includes a primary screen to determine: drug conformation of active pharmaceutical ingredient; formulation
and drug stability; in vivo pharmacokinetics (PK), and target tissue concentrations in models at disease-relevant ages. A secondary screen
evaluates target diseasemodifying activity using non-invasive positron emission tomography/magnetic resonance imaging as a pharmacodynamics
(PD) readout matched to known disease pathology in themodel. Mousemodels are best matched tomechanism of action of compound being
evaluated relative tomodel disease trajectory and pathophysiology. Compounds demonstrating positive PD effects in the secondary screen are
further interrogated via a tertiary screen of functional assays that assess the compound’s ability to normalize a disease-related phenotype in
cognition and neurophysiological tests, as well as a therapeutic index relative to any adverse effects. The final component of the PTC screen
includes confirmatory pharmacokinetics, genotyping quality control, and post treatment transcriptomics. The PTC pipeline is a National Institute
on Aging-funded resource accessible to the research community via the Screening theOptimal Pharmaceutical for Alzheimer’s Disease (STOP-AD)
program (https://stopadportal.synapse.org)
provided us knowledge of potential areas for errors in our pipeline
including those in the synthesis and formulation of drug as presented
in the present studies. Using best practices, and multiple levels of QC,
are critical for confirming appreciable exposure at the target tissue,
correlating concentration with in vivo target engagement, and identi-
fying reasons why drug may have failed to demonstrate the expected
response. Practicing these processesmay ultimately enable better pre-
clinical to clinical translation and development of effective treatments
for Alzheimer’s disease. Importantly, the preclinical screening pipeline
is an NIA-funded resource available to the research community
through the Screening the Optimal Pharmaceutical for Alzheimer’s
Disease (STOP-AD) program (https://.stopadportal.synapse.org).11
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F IGURE 2 Validation of the active
pharmaceutical ingredient of verubecestat.
Chromatogram of standard verubecestat (A),
catalog S8564, andMK-2206 (B) the internal
standard injected to liquid chromatography-mass
spectrometry (LC/MS/MS) system. The filled peak
is the analyte of interest. Chromatogram of
custom batch active pharmaceutical ingredient
(API) verubecestat (C), catalog S8564, and
MK-2206 (D) the internal standard injected to
LC/MS/MS system. The filled peak is the analyte of
interest. Chromatogram of standard verubecestat
(E) at retention time 8.953minutes, and custom
batch API verubecestat (F) at retention time 9.666
minutes determined not to be the correct API for
verubecestat, injected to liquid chromatography/
ultraviolet (LC/UV) system
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